Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) traded down 0.1% during trading on Friday . The company traded as low as $8.47 and last traded at $8.66. 180,366 shares traded hands during trading, a decline of 22% from the average session volume of 231,983 shares. The stock had previously closed at $8.67.
Traws Pharma Stock Performance
The firm has a market capitalization of $26.21 million, a PE ratio of -0.06 and a beta of 1.13. The firm’s 50-day simple moving average is $6.06.
About Traws Pharma
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Featured Stories
- Five stocks we like better than Traws Pharma
- The Most Important Warren Buffett Stock for Investors: His Own
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What is a Low P/E Ratio and What Does it Tell Investors?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Insider Trades May Not Tell You What You Think
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
